Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PSEC

Prospect Capital Corp

Feb 13 • 04:00PM ET

3.05

+0.16 5.54 %

Financial • Asset Management • USA • NASD

Peers: ARCC MAIN TCPC HTGC GSBD TSLX TPVG NMFC CGBD SLRC

| Held by: PFFA BIZD HIPS VPC PEX DVDN PCR LBO ORR

Index	-	P/E	-	EPS (ttm)	-0.82	Insider Own	18.95%	Shs Outstand	476.46M	Perf Week	15.53%
Market Cap	1.47B	Forward P/E	7.26	EPS next Y	0.42	Insider Trans	4.26%	Shs Float	391.06M	Perf Month	3.39%
Enterprise Value	4.90B	PEG	-	EPS next Q	0.11	Inst Own	18.11%	Short Float	9.32%	Perf Quarter	8.54%
Income	-356.19M	P/S	9.41	EPS this Y	-38.96%	Inst Trans	-	Short Ratio	8.80	Perf Half Y	7.02%
Sales	156.37M	P/B	0.49	EPS next Y	-10.64%	ROA	-3.40%	Short Interest	36.46M	Perf YTD	17.76%
Book/sh	6.21	P/C	38.67	EPS next 5Y	-19.61%	ROE	-4.85%	52W High	4.47 -31.77%	Perf Year	-30.05%
Cash/sh	0.08	P/FCF	6.53	EPS past 3/5Y	- -98.19%	ROIC	-5.56%	52W Low	2.45 24.49%	Perf 3Y	-60.08%
Dividend Est.	0.51 (16.72%)	EV/EBITDA	-	Sales past 3/5Y	-33.98% -20.09%	Gross Margin	-5.75%	Volatility	5.26% 3.54%	Perf 5Y	-57.99%
Dividend TTM	0.54 (17.70%)	EV/Sales	31.37	EPS Y/Y TTM	-291.60%	Oper. Margin	-64.23%	ATR (14)	0.11	Perf 10Y	-50.57%
Dividend Ex-Date	Feb 25, 2026	Quick Ratio	0.57	Sales Y/Y TTM	-64.39%	Profit Margin	-227.79%	RSI (14)	66.41	Recom	5.00
Dividend Gr. 3/5Y	-5.90% -3.58%	Current Ratio	0.57	EPS Q/Q	80.42%	SMA20	8.97%	Beta	0.84	Target Price	2.50
Payout	-	Debt/Eq	0.40	Sales Q/Q	-75.05%	SMA50	12.83%	Rel Volume	1.48	Prev Close	2.89
Employees	-	LT Debt/Eq	0.40	Earnings	Feb 09 AMC	SMA200	3.68%	Avg Volume	4.14M	Price	3.05
IPO	Jul 27, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	82.34% 12.58%	Trades		Volume	6,114,789	Change	5.54%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-25-20	Initiated	Wells Fargo	Underweight	$4.50
Apr-20-20	Downgrade	Raymond James	Mkt Perform → Underperform
Jan-22-19	Downgrade	Barclays	Equal Weight → Underweight	$7 → $6
Aug-30-17	Upgrade	Raymond James	Underperform → Mkt Perform
May-11-17	Downgrade	FBR & Co.	Outperform → Mkt Perform	$9.50 → $8.50
Aug-31-16	Reiterated	FBR Capital	Outperform	$9 → $10
Feb-11-16	Reiterated	RBC Capital Mkts	Sector Perform	$10 → $9
Jan-11-16	Downgrade	Wells Fargo	Market Perform → Underperform
Jul-01-15	Initiated	Cantor Fitzgerald	Hold
Dec-18-14	Downgrade	Barclays	Overweight → Equal Weight	$12 → $11
Dec-08-14	Reiterated	MLV & Co	Buy	$11 → $10.75
Feb-04-14	Upgrade	Wunderlich	Hold → Buy	$12
Jan-22-14	Initiated	MLV & Co	Buy	$12
Jan-21-14	Initiated	MLV & Co	Buy	$12
Dec-05-13	Initiated	Wunderlich	Hold	$12
Jan-04-13	Initiated	Barclays	Overweight	$12
Nov-12-12	Upgrade	Stifel Nicolaus	Sell → Hold
Dec-02-10	Initiated	UBS	Neutral	$9.50
Dec-21-09	Downgrade	DA Davidson	Buy → Neutral	$11.75

Show Previous Ratings

Feb-10-26 05:20PM	Prospect Capital Q2 Earnings Call Highlights (MarketBeat) +10.34%
04:01PM	Prospect Capital Corp (PSEC) Q2 2026 Earnings Call Highlights: Strong Investment Income and ... (GuruFocus.com)
08:30AM	Prospect Capital Corporation Q2 2026 Earnings Call Summary (Moby)
Feb-09-26 04:26PM	Prospect Capital: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:08PM	Prospect Capital Announces Financial Results for December 2025 (GlobeNewswire)
09:00AM	Loading…
Feb-06-26 09:00AM	Prospect Capital Schedules Second Fiscal Quarter Earnings Release and Conference Call (GlobeNewswire)
Feb-02-26 05:02AM	Wall Street Warns About a Possible Private Credit Collapse. Should Investors Worry About These Ultra-High-Yield Stocks? (Motley Fool)
Jan-08-26 04:57PM	Prospect Capital Announces Annual Meeting Update (GlobeNewswire)
Dec-16-25 04:01PM	Prospect Capital Announces Annual Meeting Update (GlobeNewswire)
Nov-18-25 01:04PM	Want $3,500 per Year in Monthly Passive Income? Invest Just $2,500 in These Dividend Stocks (24/7 Wall St.)
Nov-08-25 02:06AM	Prospect Capital Corp (PSEC) Q1 2026 Earnings Call Highlights: Strong Income Generation and ... (GuruFocus.com)
Nov-06-25 07:14PM	Prospect Capital: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +7.45%
04:14PM	Prospect Capital Announces Financial Results for September 2025 (GlobeNewswire)
Nov-05-25 07:00AM	Prospect Capital Schedules First Fiscal Quarter Earnings Release and Conference Call (GlobeNewswire)
Oct-28-25 07:00AM	Prospect Capital Corporation Announces Pricing of $167 Million 5.5% Oversubscribed Institutional Unsecured Notes Offering (GlobeNewswire)
01:14AM	Loading…
Oct-07-25 01:14AM	Why Prospect Capital Corporation (PSEC) Stands Out as a Promising BDC Dividend Stock in 2025 (Insider Monkey)
Sep-30-25 12:50PM	Prospect Capital (PSEC) Stock Is Up, What You Need To Know (StockStory)
Sep-25-25 12:41PM	Why Is Prospect Capital (PSEC) Stock Soaring Today (StockStory)
Sep-15-25 08:17AM	Prospect Capital And Thesis Capital Partners Invests $18 Million in The Ridge (Insider Monkey)
Sep-08-25 07:01AM	Prospect Capital Corporation and Affiliate Complete $18 Million Investment in The Ridge (GlobeNewswire)
Sep-02-25 01:30AM	The 5 Most Interesting Analyst Questions From Prospect Capital's Q2 Earnings Call (StockStory)
Aug-28-25 03:05AM	Prospect Capital Corp (PSEC) Q4 2025 Earnings Call Highlights: Strategic Shift to Middle Market ... (GuruFocus.com)
Aug-26-25 05:32PM	Prospect Capital (NASDAQ:PSEC) Posts Q2 Sales In Line With Estimates (StockStory)
05:17PM	Prospect Capital: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:52PM	Prospect Capital Announces Financial Results for June 2025 (GlobeNewswire)
Aug-22-25 03:32PM	Prospect Capital Schedules Fiscal Year Earnings Release and Conference Call (GlobeNewswire)
Aug-21-25 12:21AM	Prospect Capital (PSEC) Acquires QC Holdings, Here's How the Market Reacted (Insider Monkey)
Jul-29-25 01:45AM	How Prospect Capital (PSEC) Maintains One of the Highest Dividend Rates (Insider Monkey)
Jul-01-25 07:00AM	Prospect Capital Corporation Acquires QC Holdings, Inc. (GlobeNewswire)
Jun-13-25 04:01PM	Priority Income Fund Announces Redemption of its 6.125% Series I Term Preferred Stock Due 2028 (GlobeNewswire)
01:08PM	Loading…
Jun-11-25 01:08PM	Priority Income Fund Announces 17.4% Annualized Total Cash Distribution Rate (on Class R Offering Price) with Bonus and Base Common Shareholder Distributions for June 2025 through August 2025 (GlobeNewswire)
Jun-09-25 04:01PM	Prospect Capital Announces Special Meeting Update (GlobeNewswire)
Jun-03-25 08:45AM	Private Debt Investor Features Grier Eliasek in June Edition of Middle Market Direct Lending Report (GlobeNewswire)
May-19-25 12:00PM	Prospect Capital Corporation Announces Redemption of its 3.706% Notes due 2026 (GlobeNewswire)
May-12-25 04:01PM	Priority Income Fund Announces Redemption of its 6.625% Series F Term Preferred Stock Due 2027 (GlobeNewswire)
May-10-25 03:05AM	Prospect Capital Corp (PSEC) Q3 2025 Earnings Call Highlights: Strong Net Investment Income ... (GuruFocus.com)
May-09-25 09:17AM	Prospect Capital Honored for 2025 Middle-Market Deals of the Year Awards for Druid City Independent Sponsor Investment in Healthcare Industry (GlobeNewswire)
May-08-25 04:42PM	Prospect Capital: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	Prospect Capital Announces Financial Results for Fiscal March 2025 Quarter (GlobeNewswire)
May-06-25 04:10PM	Prospect Capital Schedules Third Fiscal Quarter Earnings Release and Conference Call (GlobeNewswire)
May-02-25 11:44PM	BDC Weekly Review: BDCs Are Taking Advantage Of Wider Spreads (Seeking Alpha)
Apr-30-25 04:12PM	Prospect Capital Corporation (PSEC): Among the Cheap Dividend Stocks Being Targeted by Short Sellers (Insider Monkey)
Apr-23-25 12:26PM	Fidus Investment: Irresistible Buying Opportunity (Seeking Alpha)
Apr-18-25 08:30AM	Prospect Capital Corporation Announces Results of Cash Tender Offer For Any and All of its Outstanding 3.706% Notes due 2026 (GlobeNewswire)
Apr-17-25 09:15AM	Two BDCs For 60 Cents On The Dollar: 1 To Buy And 1 To Avoid (Seeking Alpha)
Apr-16-25 10:35AM	FS KKR Capital: Buy The Tariff Tantrum, Secure A 13.7% Yield (Seeking Alpha)
Apr-13-25 09:48AM	New Mountain Finance: A 14% Yield That Is Worth Picking Up (Rating Upgrade) (Seeking Alpha)
Apr-11-25 08:30AM	QC Holdings, Inc. to be Acquired by Prospect Capital Corporation (GlobeNewswire)
Apr-09-25 08:33AM	Prospect Capital Corporation Announces Launch of Cash Tender Offer For Any and All of its Outstanding 3.706% Notes due 2026 (GlobeNewswire) +6.29%
07:00AM	Prospect Capital Corporation Hosting Upcoming Webinar: Medium Term Notes Senior Position and Attractive Income (GlobeNewswire)
Apr-03-25 07:01AM	Prospect Capital's Credit Ratings Reaffirmed Investment Grade by Egan-Jones Ratings Company (GlobeNewswire)
Mar-30-25 03:37AM	BDC Weekly Review: PSEC Gets More Bad Press (Seeking Alpha)
Mar-28-25 07:01AM	Prospect Capital's Credit Ratings Reaffirmed Investment Grade by Morningstar DBRS with Stable Trend (GlobeNewswire)
Mar-26-25 03:08PM	Golub Capital BDC's NAV, Valuation And Dividend Vs. 11 BDC Peers - Part 2 (Includes Updated Dividend Projections) (SeekingAlpha)
Mar-25-25 10:43AM	Prospect Capital Corporation (PSEC): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
07:01AM	Prospect Capital Repays March 2025 Bond and Achieves Track Record of $4.7 Billion in Cumulative Principal Bond Repayments During More Than 20 Year History (GlobeNewswire)
Mar-20-25 11:15AM	Buy 4 Ideal 'Safer' February Dividends, Out Of 40 Choices From Readers (SeekingAlpha)
01:31AM	Goldman Sachs BDC: Dividend Alignment, But Still A Buy (SeekingAlpha)
Mar-19-25 07:01AM	R-V Industries to Participate in Several Upcoming Industry Events (GlobeNewswire)
Mar-13-25 04:30PM	Priority Income Fund Announces 13.0% Annualized Total Cash Distribution Rate (on Class R Offering Price) with Bonus and Base Common Shareholder Distributions for March 2025 through May 2025 (GlobeNewswire)
07:01AM	Town & Country Living Unveils Stylish and Functional Pet Comfort Collection at Global Pet Expo 2025 (GlobeNewswire)
Mar-12-25 09:30AM	Town & Country Living Partners with Draper James to Launch Charming Cross-Category Home Collection (GlobeNewswire)
Mar-11-25 03:09PM	Priority Income Fund Announces Declaration of Preferred Stock Distributions for March 2025 (GlobeNewswire)
Mar-10-25 07:04PM	Prospect Capital Corporation Releases Updated Prospect Highlights (GlobeNewswire)
06:09PM	Mity Inc. Announces Successful Launch of Traversa Non-Emergency Medical Transport Chair (GlobeNewswire)
05:51PM	Valley Electric Received Three Separate Awards for Excellence in Engineering, Design and Sustainability (GlobeNewswire)
05:50PM	Druid City Vital Care Recognized at Vital Care Infusion Services Annual Conference (GlobeNewswire)
05:49PM	Tower Loan Announces New Customer Mobile App (GlobeNewswire)
05:31PM	Prospect Capital Achieves Outstanding Corporate Culture Recognition Based on Independent Culture Amp Survey (GlobeNewswire)
05:29PM	Prospect Capital and Refuel Agency Create a Positive Impact for Military Veterans Through Philanthropic Partnership (GlobeNewswire)
01:15PM	Priority Income Fund Announces Redemption of its 6.000% Series H Term Preferred Stock Due 2026 (GlobeNewswire)
Mar-08-25 06:50AM	Prospect Capital Corporation (PSEC): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock? (Insider Monkey)
Feb-12-25 02:08AM	Prospect Capital Corp (PSEC) Q2 2025 Earnings Call Highlights: Strong Liquidity and Secured ... (GuruFocus.com)
12:04AM	Q2 2025 Prospect Capital Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-10-25 04:09PM	Prospect Capital: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Prospect Capital Announces Financial Results for Fiscal December 2024 Quarter (GlobeNewswire)
Feb-03-25 05:00PM	Prospect Capital Schedules Second Fiscal Quarter Earnings Release and Conference Call (GlobeNewswire)
Jan-31-25 07:01AM	Prospect Capital Corporation Makes $65 Million Investment in Taos Footwear (GlobeNewswire)
Dec-19-24 05:14PM	NewStar Exchange Acquires Newly Constructed Built-to-Rent ('BTR') Community in Charlotte, North Carolina and Launches New 1031 Delaware Statutory Trust Offering (PR Newswire)
Dec-17-24 09:13AM	Prospects Private Credit Fund Gets Second Downgrade to Junk (Bloomberg)
Dec-13-24 08:30PM	KBW Announces Index Rebalancing for Fourth-Quarter 2024 (GlobeNewswire)
Dec-09-24 02:46PM	Prospect Capital Corporation Hosting Upcoming Webinar: Preferred Stock as a Low Volatility, Downside Protected, and Income Generating Asset Class (GlobeNewswire)
Dec-06-24 07:04PM	Prospect Capitals Private Credit Fund Cut to Junk by S&P (Bloomberg)
Nov-25-24 07:01AM	National Property REIT Corp. Exits Arlington Park Investment with 2.4 Times Cash on Cash Return (GlobeNewswire)
Nov-22-24 05:17PM	Priority Income Fund Announces Redemption of its 6.250% Series G Term Preferred Stock Due 2026 (GlobeNewswire)
Nov-21-24 07:01AM	National Property REIT Corp. Exits Dylan at Grayson Investment with 1.7 Times Cash on Cash Return (GlobeNewswire)
Nov-12-24 07:01AM	Prospect Capital Corporation to Present at the 2024 Markets Group NYC Private Credit Conference (GlobeNewswire)
Nov-09-24 02:07AM	Prospect Capital Corp (PSEC) Q1 2025 Earnings Call Highlights: Strong Investment Income and ... (GuruFocus.com)
Nov-08-24 01:24PM	Prospect Capital Plunges on First Dividend Cut Since 2017 (Bloomberg) -14.53%
07:10AM	Prospect Capital: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:01AM	Prospect Capital Announces Financial Results for Fiscal September 2024 Quarter (GlobeNewswire)
Nov-07-24 02:18PM	Prospect Capital Schedules First Fiscal Quarter Earnings Release and Conference Call (GlobeNewswire)
Oct-21-24 07:00AM	Prospect Capital Corporation Upsizes Preferred Stock Offering to $2.25 Billion (GlobeNewswire)
Oct-18-24 09:50AM	Prospect Capital Corporation Provides First Lien Senior Secured Term and Convertible Loans to Support the Acquisition of Druid City Infusion by Inlet Road Capital Management (GlobeNewswire)
Oct-15-24 11:31AM	Prospect Capital Corporation Closes $764 Million of New Investments in Fiscal Year June 2024 (GlobeNewswire)
Oct-14-24 01:42PM	Nails Inc. Eyes North America With Sale to Pacific World Corp. (WWD)
Oct-07-24 10:28AM	Prospect Capital Corporation Extends and Increases Revolving Credit Facility to Over $2.1 Billion of Aggregate Commitments (GlobeNewswire)
Oct-03-24 07:00AM	Prospect Capital Celebrates its 20th Anniversary as a Leading Provider of Private Debt and Equity to U.S. Middle-Market Companies with Over $20 Billion Invested and More than 300 Portfolio Company Exits (GlobeNewswire)
Sep-24-24 05:39PM	Prospects Private Debt Fund on Cusp of Junk After Outlook Cuts (Bloomberg)
Sep-18-24 06:24PM	S&P Puts $8 Billion Prospect Fund on Negative Outlook (Bloomberg)

Prospect Capital Corp., a traded business development company invests in middle market companies located in the United States. The fund targets companies operating across a broad range of sectors. It provides debt and equity financing for buyout, growth, development, and recapitalization. It acts as a co-investor and takes controlling interest. The company was founded on April 13, 2004 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eliasek M Grier	Chief Operating Officer	Feb 11 '26	Buy	2.92	942,800	2,749,770	3,443,930	Feb 13 07:00 AM
Eliasek M Grier	Chief Operating Officer	Sep 25 '25	Buy	2.71	370,000	1,002,700	2,501,130	Sep 29 04:01 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Sep 25 '25	Buy	2.72	925,000	2,517,758	86,067,158	Sep 29 04:00 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Sep 24 '25	Buy	2.62	741,158	1,939,610	85,142,158	Sep 26 04:02 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Sep 23 '25	Buy	2.66	384,000	1,021,478	84,401,000	Sep 25 04:02 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Sep 22 '25	Buy	2.66	374,500	997,219	84,017,000	Sep 24 04:02 PM
Stark Eugene S	Director	Sep 17 '25	Buy	2.79	2,500	6,975	60,000	Sep 19 03:29 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Jun 23 '25	Buy	3.16	319,000	1,008,646	83,585,026	Jun 25 04:15 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Jun 20 '25	Buy	3.19	623,300	1,988,763	83,266,026	Jun 24 04:46 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 24 '25	Buy	4.24	24,000	101,681	82,594,540	Mar 26 04:00 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 21 '25	Buy	4.26	24,000	102,250	82,570,540	Mar 25 04:06 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 20 '25	Buy	4.28	24,000	102,667	82,546,540	Mar 24 04:02 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 19 '25	Buy	4.30	24,000	103,130	82,509,933	Mar 21 04:08 PM
Gremp William	Director	Mar 18 '25	Buy	4.29	19,100	81,984	75,153	Mar 20 04:01 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 18 '25	Buy	4.30	24,000	103,222	82,485,933	Mar 20 04:01 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Buy	4.30	240,000	1,033,104	82,461,933	Mar 19 04:01 PM
Gremp William	Director	Mar 14 '25	Buy	4.24	900	3,816	56,053	Mar 18 05:29 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 14 '25	Buy	4.28	240,000	1,026,600	82,221,933	Mar 18 04:05 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 13 '25	Buy	4.20	240,000	1,009,104	81,981,933	Mar 17 04:01 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 12 '25	Buy	4.25	240,000	1,018,920	81,741,933	Mar 14 04:01 PM
Barry John F	CHIEF EXECUTIVE OFFICER	Mar 11 '25	Buy	4.32	2,000,000	8,640,000	81,501,933	Mar 13 04:01 PM

Open in Screener

IMRX

Immuneering Corp

Feb 13 • 04:00PM ET

4.93

-0.03 -0.60 %

Healthcare • Biotechnology • USA • NASD

Peers: RCKT SRRK RNA SYRS STRO CUE MGTX CABA UBX ADAP

| Held by: XBI VTI VXF IBB ITOT IWC LABU AVSC IBBQ DFAC

Index	-	P/E	-	EPS (ttm)	-1.78	Insider Own	24.65%	Shs Outstand	63.48M	Perf Week	0.00%
Market Cap	318.33M	Forward P/E	-	EPS next Y	-1.46	Insider Trans	0.47%	Shs Float	48.65M	Perf Month	11.29%
Enterprise Value	94.69M	PEG	-	EPS next Q	-0.31	Inst Own	46.83%	Short Float	23.14%	Perf Quarter	-25.53%
Income	-62.50M	P/S	-	EPS this Y	30.54%	Inst Trans	47.25%	Short Ratio	6.32	Perf Half Y	62.17%
Sales	0.00M	P/B	1.37	EPS next Y	-3.15%	ROA	-40.37%	Short Interest	11.26M	Perf YTD	-25.08%
Book/sh	3.59	P/C	1.40	EPS next 5Y	8.87%	ROE	-43.75%	52W High	10.08 -51.09%	Perf Year	165.05%
Cash/sh	3.52	P/FCF	-	EPS past 3/5Y	-16.91% -46.45%	ROIC	-26.99%	52W Low	1.10 348.18%	Perf 3Y	25.45%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.20% 7.35%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.32%	Oper. Margin	-	ATR (14)	0.40	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	24.00	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.03	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.00	EPS Q/Q	22.89%	SMA20	-0.09%	Beta	0.45	Target Price	17.17
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-11.64%	Rel Volume	0.27	Prev Close	4.96
Employees	66	LT Debt/Eq	0.02	Earnings	Nov 12 AMC	SMA200	1.07%	Avg Volume	1.78M	Price	4.93
IPO	Jul 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.14% -	Trades		Volume	477,791	Change	-0.60%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Initiated	Leerink Partners	Outperform	$15
Dec-13-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Mar-15-24	Reiterated	Needham	Buy	$20 → $15
Mar-15-24	Downgrade	TD Cowen	Outperform → Market Perform
Mar-15-24	Downgrade	Jefferies	Buy → Hold	$16 → $3
Dec-01-23	Initiated	Needham	Buy	$20
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Apr-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $14
Apr-19-23	Upgrade	Mizuho	Neutral → Buy	$10 → $20
Mar-30-23	Initiated	Mizuho	Neutral	$10
Feb-03-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$12 → $5
Jul-08-22	Initiated	Chardan Capital Markets	Buy	$18
Apr-01-22	Initiated	Oppenheimer	Outperform	$25
Jan-07-22	Initiated	Piper Sandler	Overweight	$41

Show Previous Ratings

Jan-08-26 09:28AM	Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower (Benzinga) -43.22%
05:17AM	Stock Market Today: S&P 500, Dow Jones Futures Decline - AZZ, Northrop Grumman, Immuneering In Focus (Benzinga)
Jan-07-26 07:03PM	Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3 (MarketBeat) +23.96%
04:00PM	Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (GlobeNewswire)
Dec-29-25 12:00PM	All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy (Zacks)
08:00AM	Loading…
Dec-23-25 08:00AM	Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 (GlobeNewswire) +8.12%
Dec-17-25 04:05PM	Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA (GlobeNewswire)
Dec-16-25 08:00AM	Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Nov-26-25 12:00PM	Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? (Zacks)
Nov-25-25 08:00AM	Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-12-25 04:05PM	Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates (GlobeNewswire)
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks)
Nov-04-25 04:05PM	Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 (GlobeNewswire)
09:33AM	Loading…
Oct-31-25 09:33AM	Apple upgraded, Comcast downgraded: Wall Street's top analyst calls (The Fly) +7.18%
Sep-30-25 11:42AM	Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) (Insider Monkey)
Sep-26-25 04:01PM	Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 (GlobeNewswire) -16.46%
Sep-25-25 12:08AM	Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi (GlobeNewswire) -13.33%
Sep-24-25 04:05PM	Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi (GlobeNewswire) +7.45%
04:01PM	Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (GlobeNewswire)
Sep-16-25 07:00AM	Immuneering Appoints Dr. Thomas Schall as Chairman of the Board (GlobeNewswire) +5.73%
Sep-10-25 07:00AM	Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 (GlobeNewswire) +15.46%
Aug-26-25 04:05PM	Immuneering Announces Closing of $25 Million Private Placement (GlobeNewswire) -12.33%
11:17AM	Immuneering Stock Rises 21.7% on Supply Agreement With LLY (Zacks)
Aug-25-25 08:00AM	Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib (GlobeNewswire) +21.68%
Aug-21-25 08:00AM	Immuneering Announces $25 Million Private Placement (GlobeNewswire) +34.99%
Aug-13-25 04:05PM	Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.59%
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire)
Jul-09-25 08:00AM	Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib (GlobeNewswire) +11.25%
04:00AM	Loading…
Jul-08-25 04:00AM	The MEK effect on cancer a slow and steady approach to drug resistance (Pharma Voice)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -7.58%
Jun-17-25 06:00AM	Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients (GlobeNewswire) -23.21%
Jun-16-25 08:00AM	Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 (GlobeNewswire) +24.74%
May-29-25 08:00AM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.83%
May-05-25 04:05PM	Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-02-25 08:00AM	Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 04:30PM	Immuneering Corporation Announces Grant of Inducement Award (GlobeNewswire) +9.09%
Mar-20-25 04:05PM	Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
07:12AM	Immuneering names Igor Matushansky as chief medical officer (SeekingAlpha)
07:00AM	Immuneering Names Dr. Igor Matushansky as Chief Medical Officer (GlobeNewswire)
Feb-06-25 07:00AM	Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo (cemiplimab) (GlobeNewswire)
Feb-03-25 04:05PM	Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-25 08:00AM	Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer (GlobeNewswire)
Jan-07-25 09:28AM	Why Is Immuneering Stock Trading Higher On Tuesday? (Benzinga)
07:00AM	Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +10.00%
Dec-19-24 08:00AM	Immuneering Launches Pancreatic Cancer Advisory Board (GlobeNewswire) +13.58%
Dec-17-24 08:00AM	Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025 (GlobeNewswire)
Dec-13-24 02:10PM	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? (Benzinga) -17.01%
Dec-12-24 08:00AM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma (GlobeNewswire) -7.94%
Nov-27-24 08:00AM	Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 04:05PM	Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.56% +13.45%
Oct-15-24 08:00AM	Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer (GlobeNewswire) +15.50%
Sep-13-24 08:14AM	Why Is Nanocap Immuneering Stock Trading Higher On Friday? (Benzinga) +41.26%
Sep-12-24 04:05PM	Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients (GlobeNewswire) +10.85%
Aug-29-24 08:00AM	Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:05PM	Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.06%
Jul-31-24 04:05PM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer (GlobeNewswire) +19.47%
May-29-24 04:05PM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-07-24 10:55PM	IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024 (InvestorPlace) -5.45%
04:05PM	Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-06-24 04:30PM	Immuneering Recognizes Melanoma Awareness Month (GlobeNewswire)
Apr-09-24 12:00PM	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models (GlobeNewswire)
Apr-03-24 04:05PM	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 08:00AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire)
Mar-18-24 11:02AM	Immuneering (IMRX) Plummets 71% in One Week: Here's Why (Zacks) +34.03%
Mar-14-24 07:00AM	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors (GlobeNewswire) -50.68%
Mar-12-24 08:00AM	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-11-24 08:00AM	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors (GlobeNewswire) -9.53%
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 05:00PM	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Immuneering to Participate in the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Mar-03-24 07:01PM	Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Mar-01-24 08:00AM	Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-20-24 08:00AM	Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer (GlobeNewswire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +8.00%
Feb-01-24 08:00AM	Immuneering Announces Participation in February Investor Conferences (GlobeNewswire)
Dec-12-23 08:00AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire) -7.11%
Nov-20-23 04:05PM	Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +25.45%
Nov-09-23 04:05PM	Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -11.86%
Oct-12-23 04:05PM	Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference (GlobeNewswire) -6.65%
Oct-04-23 04:05PM	Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-23 08:00AM	Immuneering to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire)
Aug-03-23 04:05PM	Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-02-23 06:09AM	Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership (Simply Wall St.)
Jul-05-23 09:55AM	Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet (Zacks)
Jun-05-23 08:00AM	Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors (GlobeNewswire)
May-30-23 08:00AM	Immuneering to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.86%
May-04-23 07:25PM	Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.75%
04:05PM	Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-18-23 09:24AM	Immuneering Announces $30 Million Underwritten Offering (GlobeNewswire) +9.60%
09:00AM	Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline (GlobeNewswire)
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-12-23 04:05PM	Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-11-23 03:56AM	Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains? (Zacks) +5.78%
Apr-05-23 08:00AM	Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-28-23 08:00AM	Immuneering Appoints Harold E. Brakewood as Chief Business Officer (GlobeNewswire) -7.40%
Mar-27-23 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade (Zacks)

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brakewood Harold Eugene	Chief Business Officer	Jan 16 '26	Buy	4.76	5,250	24,990	11,050	Jan 21 09:09 AM
Schall Thomas J.	Director	Jan 15 '26	Buy	4.67	21,645	101,041	74,530	Jan 20 09:17 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jan 15 '26	Buy	4.57	2,298	10,502	376,496	Jan 16 04:07 PM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Jan 13 '26	Buy	4.15	2,626	10,906	25,970	Jan 15 08:06 AM
Feinberg Peter	Director	Jan 12 '26	Buy	4.35	20,000	86,904	135,441	Jan 14 08:10 AM
Feinberg Peter	Director	Oct 03 '25	Buy	6.67	7,500	50,025	156,766	Oct 07 08:56 AM
Morales Mallory	Chief Accounting Officer	Oct 01 '25	Buy	6.39	300	1,917	27,533	Oct 02 09:02 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Oct 01 '25	Buy	6.38	800	5,103	23,344	Oct 02 08:57 AM
Bookman Michael	CHIEF LEGAL OFFICER, SECRETARY	Oct 01 '25	Buy	6.83	1,020	6,966	4,870	Oct 02 08:52 AM
Feinberg Peter	Director	Sep 30 '25	Buy	7.03	7,500	52,730	149,266	Oct 01 08:59 AM
Feinberg Peter	Director	Sep 29 '25	Buy	7.18	5,000	35,900	141,766	Sep 30 09:00 AM
BERMAN ANN E	Director	Sep 23 '25	Proposed Sale	9.72	14,000	136,080		Sep 23 08:48 AM
HAUSMAN DIANA	Director	Jul 02 '25	Buy	3.62	3,000	10,874	3,000	Jul 07 08:59 AM
HAUSMAN DIANA	Director	Jul 02 '25	Buy	3.60	2,500	8,989	2,500	Jul 07 08:59 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Jul 02 '25	Buy	3.57	700	2,499	10,729	Jul 07 08:52 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 02 '25	Buy	3.53	7,015	24,792	2,312,852	Jul 03 09:12 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 01 '25	Buy	3.38	2,985	10,087	2,305,837	Jul 03 09:12 AM
Schall Thomas J.	Director	Jun 27 '25	Buy	3.66	9,500	34,788	52,885	Jun 30 09:09 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 20 '25	Buy	2.70	7,415	20,020	353,311	Jun 24 09:01 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 23 '25	Buy	2.43	6,007	14,596	359,318	Jun 24 09:01 AM
Brakewood Harold Eugene	Chief Business Officer	Jun 20 '25	Buy	2.53	1,900	4,804	5,800	Jun 24 08:52 AM
Feinberg Peter	Director	Jun 18 '25	Buy	2.53	25,000	63,188	136,766	Jun 23 09:09 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jun 18 '25	Buy	2.39	21,000	50,144	2,302,852	Jun 20 09:09 AM
Schall Thomas J.	Director	Jun 17 '25	Buy	2.21	40,485	89,278	43,385	Jun 18 09:11 AM

Open in Screener

RZLT

Rezolute Inc

Feb 13 • 04:00PM ET

3.84

+0.21 5.79 %

Healthcare • Biotechnology • USA • NASD

Peers: ASND KRYS SWTX LGND RAPT SVRA IMTX UBX RKDA

| Held by: XBI IWM VTI IWO VXF SCHA VTWO IWC BBC VHT

Index	RUT	P/E	-	EPS (ttm)	-0.92	Insider Own	20.39%	Shs Outstand	95.55M	Perf Week	23.08%
Market Cap	356.08M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	0.65%	Shs Float	76.18M	Perf Month	41.18%
Enterprise Value	224.42M	PEG	-	EPS next Q	-0.17	Inst Own	103.62%	Short Float	24.91%	Perf Quarter	-61.60%
Income	-84.23M	P/S	-	EPS this Y	24.80%	Inst Trans	3.88%	Short Ratio	2.71	Perf Half Y	-40.56%
Sales	0.00M	P/B	2.87	EPS next Y	0.68%	ROA	-67.21%	Short Interest	18.98M	Perf YTD	62.71%
Book/sh	1.34	P/C	2.68	EPS next 5Y	18.44%	ROE	-74.02%	52W High	11.46 -66.48%	Perf Year	-20.17%
Cash/sh	1.43	P/FCF	-	EPS past 3/5Y	24.95% 22.65%	ROIC	-65.49%	52W Low	1.07 258.88%	Perf 3Y	42.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.53% 9.40%	Perf 5Y	-68.41%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	24.34%	Oper. Margin	-	ATR (14)	0.36	Perf 10Y	-93.02%
Dividend Ex-Date	-	Quick Ratio	14.18	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.72	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	14.18	EPS Q/Q	2.36%	SMA20	18.78%	Beta	0.49	Target Price	4.75
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	7.59%	Rel Volume	0.90	Prev Close	3.63
Employees	71	LT Debt/Eq	0.00	Earnings	Feb 12 AMC	SMA200	-35.27%	Avg Volume	7.01M	Price	3.84
IPO	May 08, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.77% -	Trades		Volume	6,327,164	Change	5.79%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-25	Downgrade	Wedbush	Outperform → Neutral	$1
Dec-11-25	Downgrade	Craig Hallum	Buy → Hold	$2
Dec-11-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-05-24	Initiated	Wedbush	Outperform	$12
Aug-27-24	Initiated	Guggenheim	Buy	$11
Jul-17-24	Initiated	BTIG Research	Buy	$13
Jun-04-24	Initiated	Craig Hallum	Buy	$14
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

Show Previous Ratings

Feb-12-26 04:05PM	Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire) +7.72% +5.79%
Feb-04-26 07:00AM	Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.62%
Jan-14-26 11:58AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +9.68%
Jan-07-26 07:00AM	Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism (GlobeNewswire) +23.04%
Dec-31-25 11:12AM	Rezolute's Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing (Insider Monkey) +7.76%
04:39PM	Loading…
Dec-30-25 04:39PM	Insiders Made Their Bets in 2025-These Were the Top 5 Stocks They Bought (MarketBeat) -9.88%
Dec-23-25 09:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +18.05%
Dec-18-25 01:49PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) -7.96%
Dec-17-25 09:47AM	RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know (Zacks)
Dec-15-25 01:06PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating RZLT Investors with Losses Encouraged to Contact the Firm (PR Newswire) -9.44%
09:35AM	Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround (Zacks)
Dec-12-25 12:28PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily) +28.57%
11:52AM	Rezolute stock crashes after sole pipeline candidate fails Phase III (Clinical Trials Arena)
08:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire)
05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
07:59PM	Loading…
Dec-11-25 07:59PM	Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure (Business Wire) -87.20%
06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
07:00AM	Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in Rezolute (RZLT)? Wall Street Analysts Think 56.58% (Zacks) -5.66%
Nov-12-25 12:00PM	All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy (Zacks)
09:55AM	Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-10-25 05:30PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.48%
Nov-06-25 04:05PM	Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire) +12.08%
Nov-05-25 07:30AM	Rezolute to Host Virtual Investor Event on Ersodetug Development Program (GlobeNewswire) +5.06%
Oct-29-25 11:57AM	Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy (Insider Monkey)
Oct-15-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.89%
Oct-09-25 04:05PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.34%
Sep-17-25 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire) +6.36%
07:05AM	Rezolute Stock: FDA Fast Track Fuels 2025 Breakout (MarketBeat)
Sep-02-25 07:30AM	Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism (GlobeNewswire)
07:30AM	Loading…
Aug-27-25 07:30AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 07:30AM	Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer (GlobeNewswire)
Aug-13-25 07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Jul-22-25 07:30AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-09-25 07:30AM	Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) (GlobeNewswire) +6.24%
May-28-25 08:00AM	Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism (GlobeNewswire)
May-20-25 12:08PM	Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential (Insider Monkey)
May-13-25 04:05PM	Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-05-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
May-01-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.32%
03:57AM	Rezolute: RZ402 Could Be A Surprise Candidate In The Making (Seeking Alpha)
Apr-25-25 04:30PM	Rezolute, Inc. Announces Closing of Underwritten Offering (GlobeNewswire)
Apr-23-25 08:05AM	Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) +27.65%
08:00AM	Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ( HI ) (GlobeNewswire)
Apr-11-25 12:00PM	Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-26-25 07:30AM	Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors (GlobeNewswire) -5.54%
Feb-12-25 04:05PM	Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-04-25 08:00AM	Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Jan-31-25 08:00AM	Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-07-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-05-24 08:00AM	Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 08:00AM	FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Nov-07-24 04:05PM	Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-19-24 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.39%
Sep-09-24 07:30AM	FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study (GlobeNewswire) +22.07%
Aug-27-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-24 07:30AM	Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Jul-31-24 08:00AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-27-24 08:00AM	Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire)
Jun-24-24 08:00AM	Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds (GlobeNewswire) +7.85%
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -23.45%
Jun-13-24 11:30PM	Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.84%
04:01PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-30-24 08:00AM	Rezolute to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire) +13.76%
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)
Nov-13-23 04:05PM	Rezolute Reports First Quarter Fiscal 2024 Results (GlobeNewswire) +12.22% -7.39%
Oct-17-23 08:00AM	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +6.52%
Oct-11-23 08:00AM	Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism (GlobeNewswire) -6.00%
Sep-14-23 04:05PM	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Sep-06-23 07:00AM	Rezolute to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Jun-27-23 04:05PM	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile) -7.51%
May-11-23 04:05PM	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Mar-23-23 04:50PM	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema (GlobeNewswire) -5.34%
Mar-08-23 07:00AM	Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert (GlobeNewswire) +7.44%
Feb-10-23 04:05PM	Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Dec-15-22 07:00AM	Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema (GlobeNewswire)
Nov-09-22 04:05PM	Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Nov-01-22 07:00AM	Rezolute to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-22 07:00AM	Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting (GlobeNewswire)
Sep-15-22 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress (GlobeNewswire)
Sep-07-22 07:00AM	Rezolute Announces Presentation at the 60th Annual ESPE Meeting (GlobeNewswire)
Aug-15-22 08:36AM	Here's What Rezolute, Inc.'s (NASDAQ:RZLT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-01-22 07:00AM	Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer (GlobeNewswire)
May-12-22 04:05PM	Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire) +6.15%

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hogenhuis Wladimir	Director	Dec 16 '25	Buy	1.69	5,650	9,548	119,675	Dec 17 04:14 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Dec 16 '25	Buy	1.70	28,000	47,600	308,352	Dec 17 04:13 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.77	40,000	70,640	415,900	Dec 15 07:35 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.79	5,000	8,938	7,000	Dec 15 07:35 PM
Elam Nevan C	CEO	Dec 15 '25	Buy	1.59	32,000	50,880	641,119	Dec 15 07:35 PM
Karnawat Sunil Ratilal	Chief Commercial Officer	Dec 15 '25	Buy	1.62	12,100	19,599	71,542	Dec 15 07:34 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 25 '25	Buy	4.38	2,500	10,939	15,500	Jun 26 09:07 AM
Evans Daron	CFO	Jun 24 '25	Buy	4.05	5,000	20,250	268,900	Jun 24 12:41 PM
Kim Young-Jin	Director	Jun 13 '25	Buy	3.25	1,230,769	3,999,999	8,423,386	Jun 23 09:38 AM
KREHER NERISSA	Director	Jun 13 '25	Buy	3.25	3,076	9,997	37,576	Jun 23 09:12 AM
Hogenhuis Wladimir	Director	Mar 31 '25	Buy	2.92	6,758	19,733	84,025	Apr 01 03:52 PM
Elam Nevan C	CEO	Mar 27 '25	Buy	2.85	12,302	34,999	224,119	Mar 31 09:18 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.89	10,000	28,900	237,900	Mar 28 08:40 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.88	10,000	28,800	23,000	Mar 28 08:40 AM
Hogenhuis Wladimir	Director	Feb 18 '25	Buy	4.70	10,000	47,000	77,267	Feb 20 07:59 PM
Evans Daron	CFO	Dec 09 '25	Buy	5.04	10,549	53,167	131,900	Dec 10 09:11 AM

Open in Screener

AKTX

Akari Therapeutics Plc ADR

Feb 13 • 04:00PM ET

0.2330

-0.0050 -2.10 %

Healthcare • Biotechnology • USA • NASD

AKTX Akari Therapeutics Plc ADR daily Stock Chart

Peers: REGN ALNY NBIX ARGX ADAP FATE CLLS TGTX MCRB VCNX

Index	-	P/E	-	EPS (ttm)	-0.48	Insider Own	0.40%	Shs Outstand	32.61M	Perf Week	-0.85%
Market Cap	7.60M	Forward P/E	-	EPS next Y	-0.19	Insider Trans	19.19%	Shs Float	32.48M	Perf Month	-12.90%
Enterprise Value	7.18M	PEG	-	EPS next Q	-0.05	Inst Own	5.25%	Short Float	0.74%	Perf Quarter	-57.08%
Income	-15.72M	P/S	-	EPS this Y	83.92%	Inst Trans	36.18%	Short Ratio	0.23	Perf Half Y	-75.98%
Sales	0.00M	P/B	0.33	EPS next Y	14.71%	ROA	-65.35%	Short Interest	0.24M	Perf YTD	-19.38%
Book/sh	0.70	P/C	2.99	EPS next 5Y	46.44%	ROE	-196.60%	52W High	1.73 -86.53%	Perf Year	-78.56%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	- -	ROIC	-69.30%	52W Low	0.22 6.98%	Perf 3Y	-97.61%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.70% 10.06%	Perf 5Y	-99.59%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	13.57%	Oper. Margin	-	ATR (14)	0.03	Perf 10Y	-99.89%
Dividend Ex-Date	-	Quick Ratio	0.19	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.68	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.19	EPS Q/Q	17.94%	SMA20	-6.45%	Beta	0.29	Target Price	3.33
Payout	-	Debt/Eq	0.09	Sales Q/Q	-	SMA50	-16.58%	Rel Volume	0.13	Prev Close	0.24
Employees	9	LT Debt/Eq	0.00	Earnings	Dec 05	SMA200	-71.02%	Avg Volume	1.06M	Price	0.23
IPO	May 07, 2013	Option/Short	No / Yes	EPS/Sales Surpr.	-100.00% -	Trades		Volume	134,864	Change	-2.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Initiated	Ladenburg Thalmann	Buy	$1
Jul-18-25	Initiated	Maxim Group	Buy	$5
Jan-04-19	Upgrade	B. Riley FBR	Neutral → Buy	$2.50 → $3
Feb-08-18	Initiated	B. Riley FBR, Inc.	Neutral	$3
Sep-22-17	Upgrade	William Blair	Mkt Perform → Outperform
May-31-17	Upgrade	Chardan Capital Markets	Sell → Neutral	$6
Apr-17-17	Reiterated	Chardan Capital Markets	Sell	$6.50 → $5
Jul-11-16	Initiated	Chardan Capital Markets	Sell	$5

Feb-11-26 08:45AM	Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing the Company's Expanded ADC Pipeline (GlobeNewswire)
Feb-05-26 09:15AM	Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire)
Jan-26-26 08:45AM	Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors (GlobeNewswire)
Jan-17-26 07:00AM	MarketBeat Week in Review - 01/12 - 01/16 (MarketBeat)
Jan-09-26 09:00AM	Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 (GlobeNewswire)
09:15AM	Loading…
Jan-08-26 09:15AM	Akari Therapeutics to Present at the 2026 Biotech Showcase (GlobeNewswire)
Dec-30-25 09:15AM	Akari Therapeutics Issues 2025 End of Year Letter to Shareholders (GlobeNewswire)
Dec-23-25 08:30AM	Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial (GlobeNewswire) -7.08%
Dec-18-25 08:30AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Dec-16-25 09:29AM	Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market (GlobeNewswire) -38.30%
Dec-09-25 08:40AM	Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer (GlobeNewswire)
Dec-04-25 09:00AM	Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment (GlobeNewswire)
Nov-25-25 09:00AM	Akari Therapeutics Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Nov-18-25 08:35AM	Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer (GlobeNewswire) +12.04%
Nov-10-25 08:30AM	Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors (GlobeNewswire)
09:25AM	Loading…
Nov-04-25 09:25AM	Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available (GlobeNewswire) +13.10%
Oct-30-25 08:35AM	Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP (GlobeNewswire)
Oct-22-25 09:05AM	Akari Therapeutics Announces Launch of CEO Corner Platform (GlobeNewswire)
Oct-15-25 08:30AM	Akari Therapeutics Announces $2.5 Million Registered Direct Offering (GlobeNewswire) -16.34%
Oct-10-25 08:50AM	Akari Therapeutics files two new patents with USPTO (TipRanks) -8.82%
Oct-09-25 08:45AM	Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 (GlobeNewswire)
Oct-03-25 09:30AM	Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire)
Sep-24-25 08:45AM	Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 (GlobeNewswire) +45.96%
Sep-17-25 08:45AM	Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer (GlobeNewswire) +5.11%
Sep-05-25 06:45AM	Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +12.15%
Sep-03-25 08:30AM	Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -6.42%
Aug-14-25 09:15AM	Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Jul-29-25 09:15AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Jul-23-25 08:55AM	Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers (GlobeNewswire)
Jul-22-25 08:45AM	Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	Loading…
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jun-25-25 09:00AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent (GlobeNewswire)
Jun-18-25 08:50AM	Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India (GlobeNewswire)
May-29-25 09:15AM	Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology (GlobeNewswire)
May-22-25 09:00AM	Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire)
May-15-25 08:05AM	Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-25 08:45AM	Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology (GlobeNewswire)
Apr-22-25 09:05AM	Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala (GlobeNewswire) +6.25%
Apr-16-25 08:00AM	Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.24%
Mar-20-25 08:44AM	Akari Therapeutics appoints Abizer Gaslightwala as CEO (SeekingAlpha) +20.00%
08:35AM	Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer (GlobeNewswire)
Mar-03-25 09:00AM	Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules (GlobeNewswire) +7.70%
Feb-19-25 09:00AM	Akari Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire) +5.30%
Feb-03-25 08:00AM	Akari Therapeutics Joins Webull Corporate Connect Service Platform (GlobeNewswire) +9.17%
Dec-18-24 08:51AM	Akari Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
Dec-16-24 09:05AM	Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer (GlobeNewswire)
Nov-19-24 08:00AM	Akari Therapeutics Regains Full Nasdaq Compliance (GlobeNewswire) -31.44%
Nov-14-24 04:15PM	Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio (GlobeNewswire) -6.73%
Nov-08-24 08:00AM	Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger (GlobeNewswire)
Oct-15-24 08:00AM	Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger (GlobeNewswire)
Sep-17-24 08:00AM	Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics (GlobeNewswire)
Aug-19-24 04:15PM	Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) +5.42%
08:00AM	Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy (GlobeNewswire)
Jun-05-24 08:00AM	Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders (GlobeNewswire) +9.88%
Jun-04-24 08:00AM	Akari Therapeutics Secures $7.6 Million in Upsized Financing Round (GlobeNewswire) +14.20%
May-16-24 08:00AM	Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
May-01-24 08:01AM	Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics (GlobeNewswire) +10.39%
08:00AM	Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity (GlobeNewswire)
Apr-15-24 08:00AM	Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 (GlobeNewswire)
Apr-01-24 06:30AM	Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights (GlobeNewswire) -19.03%
Mar-08-24 04:38PM	Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm (GlobeNewswire)
Mar-05-24 08:00AM	Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit (GlobeNewswire)
Jan-02-24 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing (GlobeNewswire) -7.16%
Dec-14-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2024 (GlobeNewswire) +5.84%
Dec-01-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors (GlobeNewswire) +9.49%
Nov-16-23 08:00AM	Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Nov-06-23 08:00AM	Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) -5.21%
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire) +6.30%
Sep-29-23 08:00AM	Akari Therapeutics Reports First Half 2023 Financial Results and Highlights (GlobeNewswire)
Sep-27-23 08:00AM	Akari Therapeutics to Present at Emerging Growth Conference (GlobeNewswire)
Sep-21-23 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit (GlobeNewswire)
Sep-19-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs (GlobeNewswire)
Sep-05-23 08:00AM	Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.59%
Aug-21-23 02:01PM	British pharma opens U.S. headquarters in Boston (American City Business Journals)
Aug-18-23 08:00AM	Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials (GlobeNewswire) +10.00%
Aug-15-23 08:00AM	Akari Therapeutics, Plc Announces ADS Ratio Change (GlobeNewswire) -21.20%
Aug-02-23 08:00AM	Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Aug-01-23 07:30AM	Here's Why Akari Therapeutics (NASDAQ:AKTX) Must Use Its Cash Wisely (Simply Wall St.) +7.13%
Jul-27-23 08:00AM	Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire) +7.94%
Jul-19-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer (GlobeNewswire)
Jul-13-23 08:00AM	Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA (GlobeNewswire) +6.15%
Jul-11-23 08:00AM	Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy (GlobeNewswire)
Jul-06-23 08:00AM	Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire)
Jul-05-23 08:00AM	Akari Therapeutics Appoints Industry Veteran Wael Hashad to Board of Directors (GlobeNewswire)
May-16-23 04:05PM	Aspira Womens Health Names Torsten Hombeck as Chief Financial Officer (GlobeNewswire) +12.28%
08:00AM	Akari Therapeutics to Participate in A.G.P.s Virtual Healthcare Conference (GlobeNewswire)
May-01-23 08:00AM	Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights (GlobeNewswire)
Apr-25-23 04:15PM	Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement (GlobeNewswire) +6.31%
Apr-19-23 02:01PM	Insiders rewarded with a US$607k addition on top of their US$1.3m purchase as Akari Therapeutics, Plc (NASDAQ:AKTX) hits US$22m (Simply Wall St.)
Apr-14-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs (GlobeNewswire) +5.26%
Apr-11-23 08:00AM	Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology (GlobeNewswire)
Apr-03-23 08:00AM	Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting (GlobeNewswire) +12.00%
Mar-30-23 09:09AM	Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering (GlobeNewswire) -16.34%
Mar-29-23 08:00AM	Poland and U.K. Regulatory Authorities URPL and MHRA Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study (GlobeNewswire) -5.23%
Feb-21-23 08:00AM	Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings (GlobeNewswire) -10.88%
Feb-15-23 08:00AM	Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA) (GlobeNewswire)
Feb-13-23 08:00AM	Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults (GlobeNewswire)
Jan-04-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2023 (GlobeNewswire) +5.09%

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gaslightwala Abizer	CEO	Aug 21 '25	Buy	0.94	10,000	9,400	287,574	Aug 29 04:55 PM
Gaslightwala Abizer	CEO	Aug 22 '25	Buy	0.93	8,000	7,440	295,574	Aug 29 04:55 PM
Gaslightwala Abizer	CEO	Aug 25 '25	Buy	0.90	3,000	2,700	298,574	Aug 29 04:55 PM
Gaslightwala Abizer	President & CEO	Jun 24 '25	Buy	1.16	5,203	6,035	277,574	Jun 25 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 23 '25	Buy	1.15	943	1,084	272,371	Jun 25 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 20 '25	Buy	1.20	10,000	12,000	271,428	Jun 24 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 17 '25	Buy	1.20	15,000	18,000	261,428	Jun 20 04:05 PM

Open in Screener

MDBH

MDB Capital Holdings LLC

Feb 13 • 04:00PM ET

3.12

-0.03 -0.95 %

Financial • Capital Markets • USA • NASD

MDBH MDB Capital Holdings LLC daily Stock Chart

Peers: GS MS JPM BAC C WFC BK USB STT SCHW

Index	-	P/E	2.71	EPS (ttm)	1.15	Insider Own	55.44%	Shs Outstand	5.14M	Perf Week	-2.65%
Market Cap	31.69M	Forward P/E	-	EPS next Y	-	Insider Trans	0.63%	Shs Float	4.46M	Perf Month	-14.62%
Enterprise Value	16.29M	PEG	-	EPS next Q	-	Inst Own	1.64%	Short Float	0.05%	Perf Quarter	-10.71%
Income	11.43M	P/S	8.19	EPS this Y	-	Inst Trans	8.15%	Short Ratio	0.18	Perf Half Y	-8.09%
Sales	3.87M	P/B	0.53	EPS next Y	-	ROA	23.87%	Short Interest	0.00M	Perf YTD	-3.70%
Book/sh	5.89	P/C	1.99	EPS next 5Y	-	ROE	25.75%	52W High	7.98 -60.84%	Perf Year	-49.68%
Cash/sh	1.57	P/FCF	-	EPS past 3/5Y	- -	ROIC	19.13%	52W Low	3.00 4.17%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-4.66% -30.89%	Gross Margin	-	Volatility	3.92% 5.15%	Perf 5Y	-
Dividend TTM	-	EV/Sales	4.21	EPS Y/Y TTM	142.17%	Oper. Margin	-607.80%	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.40	Sales Y/Y TTM	121.21%	Profit Margin	295.58%	RSI (14)	43.04	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	9.40	EPS Q/Q	48.53%	SMA20	-5.30%	Beta	1.03	Target Price	-
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-75.48%	SMA50	-7.17%	Rel Volume	0.43	Prev Close	3.15
Employees	16	LT Debt/Eq	0.00	Earnings	Nov 20 AMC	SMA200	-17.36%	Avg Volume	11.82K	Price	3.12
IPO	Sep 21, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	5,121	Change	-0.95%

Feb-02-26 07:30PM	MDB Capital Holdings Announces Transitions In Its Board of Directors (GlobeNewswire)
Jan-14-26 12:35PM	PatentVest Releases New Report on the IP Battle Shaping the $1.8 Trillion Space Economy (GlobeNewswire) +6.71%
Nov-20-25 04:05PM	MDB Capital Holdings Provides Third Quarter 2025 Update (GlobeNewswire)
Nov-11-25 09:00AM	MDB Capital Holdings to Host Third Quarter 2025 Update Conference Call on Thursday November 20, 2025, at 4:30 p.m. Eastern Time (GlobeNewswire)
Oct-28-25 01:50PM	New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $133B Cardiac Diagnostics Market (GlobeNewswire) -6.76%
12:30PM	Loading…
Oct-06-25 12:30PM	MDB Capital Holdings, LLC to Present at the LD Micro Main Event XIX (Newsfile)
12:34AM	LD Micro Celebrates the 2,000th Company: MDB Capital Holdings (MDBH) (Newsfile)
Sep-24-25 09:00AM	PatentVest Welcomes Dr. Sarah Cork as Senior Patent Attorney, Expanding Life Sciences IP Leadership (GlobeNewswire)
Aug-27-25 04:05PM	MDB Capital Holdings Provides Second Quarter 2025 Update (GlobeNewswire)
09:00AM	PatentVest and Docana Announce Strategic Partnership to Accelerate IP Strategy and AI Innovation (GlobeNewswire)
Aug-19-25 02:30PM	PatentVest Releases First-Ever Quantum Computing Rankings (GlobeNewswire)
Aug-14-25 04:35PM	MDB Capital Holdings to Host Second Quarter 2025 Update Conference Call on Wednesday August 27, 2025, at 4:30 p.m. Eastern Time (GlobeNewswire) -6.59%
Jul-10-25 12:00PM	New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $188B Surgical Robotics Market (GlobeNewswire)
Jun-02-25 05:20PM	MDB Capital Holdings Announces Transitions In Its Board of Directors (GlobeNewswire)
May-27-25 04:05PM	ClearSign Technologies Corporation Announces Changes to Board of Directors (PR Newswire) -6.40%
09:00AM	Loading…
May-21-25 09:00AM	MDB Capital Holdings Provides First Quarter 2025 Update (GlobeNewswire)
May-14-25 12:00PM	New PatentVest Pulse Report Reveals IP Gaps in Billion-Dollar Humanoid Robotics Startups (GlobeNewswire)
08:55AM	MDB Capital Holdings to Host First Quarter 2025 Results Conference Call on Wednesday May 21, 2025, at 4:30 p.m. Eastern Time (GlobeNewswire)
Apr-23-25 07:53AM	Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio (Newsfile)
Apr-03-25 11:16AM	MDB Capital Holdings, LLC (MDBH) Q4 2024 Earnings Call Transcript (Seeking Alpha)
Apr-01-25 10:00AM	New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $400B Brain-Computer Interface (BCI) Market (GlobeNewswire)
Mar-31-25 04:05PM	MDB Capital Holdings Provides Fourth Quarter and Full Year 2024 Update (GlobeNewswire)
Mar-24-25 08:50AM	MDB Capital Holdings to Host Fourth Quarter and Full Year 2024 Results Conference Call on Monday March 31, 2025, at 4:30 p.m. Eastern Time (GlobeNewswire)
Mar-05-25 10:00AM	New PatentVest Pulse Report Reveals Transformative Trends in the AI Data Center Patent Race (GlobeNewswire)
Feb-19-25 08:25AM	eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering (GlobeNewswire) +6.58%
Feb-12-25 08:50AM	Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes (GlobeNewswire)
Feb-10-25 11:00AM	Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol (GlobeNewswire)
Jan-07-25 10:00AM	Rethinking Diabetes Care: PatentVest Pulse Unveils Key Insights on the Expanding CGM Market and the Innovations Driving Change (GlobeNewswire)
Nov-21-24 04:05PM	MDB Capital Holdings Provides Third Quarter 2024 Update (GlobeNewswire) +7.83% -9.72%
Nov-19-24 09:05AM	Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities (GlobeNewswire)
09:05AM	Loading…
Nov-15-24 09:05AM	MDB Capital Holdings to Host Third Quarter 2024 Results Conference Call on Thursday November 21, 2024, at 4:30 p.m. Eastern Time (GlobeNewswire)
Nov-14-24 04:05PM	Invizyne Technologies Announces Closing of Initial Public Offering (GlobeNewswire)
Nov-13-24 04:05PM	Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing (GlobeNewswire)
09:05AM	Invizyne Technologies Begins Trading on NASDAQ (GlobeNewswire)
Nov-12-24 10:52AM	Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024 (GlobeNewswire)
Nov-11-24 04:05PM	Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering (GlobeNewswire)
Oct-16-24 12:02PM	MDB Capital Teams with TCA Venture Group to Bring New Insights and Public Venture Opportunities to Angel Investors (GlobeNewswire)
Aug-13-24 10:53PM	MDBH Stock Earnings: MDB Capital Holdings Reported Results for Q2 2024 (InvestorPlace)
Jul-11-24 04:05PM	MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies (GlobeNewswire)
Jul-09-24 11:00AM	Recently Published Whitepaper from PatentVest Delves into Transformative Innovations in MASH Diagnostics (GlobeNewswire)
Jul-08-24 04:16PM	MDB Capital Collaborates with Mayo Clinic to Advance Anti-Senescence Platform (GlobeNewswire)
Jun-20-24 09:15AM	MDB Capital Expands Board, Appoints Daniel Torpey as New Director (GlobeNewswire)
May-22-24 11:00AM	New PatentVest Pulse Report Reveals Transformative Trends in Portable ECG Monitoring (GlobeNewswire)
09:15AM	MDB Capital Holdings Unveils Unified Corporate Branding (GlobeNewswire)
May-13-24 09:55PM	MDBH Stock Earnings: MDB Capital Holdings Reported Results for Q1 2024 (InvestorPlace)
May-07-24 01:52PM	Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq (GlobeNewswire)
Apr-17-24 04:05PM	MDB Capital Holdings Year-End Update (GlobeNewswire)
Apr-11-24 04:05PM	MDB Capital Holdings to Host Fourth Quarter 2023 and Fiscal Year 2023 Results Webinar on Wednesday April 17, 2024 at 4:30 PM Eastern Time (GlobeNewswire)
Apr-02-24 07:53AM	MDBH Stock Earnings: MDB Capital Holdings Reported Results for Q4 2023 (InvestorPlace)
Mar-15-24 02:30PM	Gain Therapeutics to Present at Public Ventures Discovery Day (GlobeNewswire)
Feb-12-24 08:00AM	Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq (GlobeNewswire)
Jan-31-24 09:00AM	MDB Capital Holdings Issues Annual Letter to Shareholders (GlobeNewswire)
Nov-15-23 04:05PM	MDB Capital Holdings Reports Third Quarter 2023 Results (GlobeNewswire)
Nov-08-23 04:05PM	Michael Burns Joins Invizyne as Executive Vice President of Energy Transition (GlobeNewswire)
Nov-02-23 04:05PM	MDB Capital Holdings to Host Third Quarter 2023 Results Conference Call on November 15, 2023 at 4:30 PM Eastern Time (GlobeNewswire)
Oct-17-23 10:00AM	Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort (GlobeNewswire)
Oct-11-23 11:10AM	Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy (GlobeNewswire)
Sep-21-23 09:00AM	MDB Capital Holdings Begins Trading on NASDAQ (ACCESSWIRE)

MDB Capital Holdings LLC is an investment holding company, which engages the provision of a foundational platform specializing in financing startups, partnering with co-founders, and fostering significant value creation. It operates through the following segments: Broker Dealer and Intellectual Property Service, Technology Development, and Other. The Broker Dealer and Intellectual Property Service segment includes Public Ventures and PatentVest. The Technology Development segment is involved in Invizyne. The Other segment focuses on non-income generating subsidiaries for management of the business including MDB CG Management Company, Inc. The company was founded by Christopher Anthony Marlett in 1997 and is headquartered in Addison, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
James Jeremy William	CFO	Jan 23 '26	Sale	3.34	60	200	23,279	Jan 27 08:19 PM
MARLETT CHRISTOPHER A	Co-Founder	Jan 02 '26	Buy	3.50	1,213	4,246	169,933	Jan 05 08:24 PM
MARLETT CHRISTOPHER A	Co-Founder	Dec 31 '25	Buy	3.35	4,387	14,696	166,720	Dec 31 04:34 PM
MARLETT CHRISTOPHER A	Co-Founder	Dec 30 '25	Buy	3.18	4,400	13,992	162,333	Dec 31 04:34 PM
Meline Susanne	Director	Aug 14 '25	Option Exercise	3.40	10,000	34,000	30,000	Dec 23 04:32 PM
Brandon George Hugh	President	Dec 09 '25	Buy	3.38	3,700	12,506	105,248	Dec 11 07:59 AM
Brandon George Hugh	President	Dec 04 '25	Buy	3.52	1,900	6,688	100,048	Dec 08 05:39 PM
Brandon George Hugh	President	Dec 05 '25	Buy	3.29	900	2,961	100,948	Dec 08 05:39 PM
Brandon George Hugh	President	Dec 08 '25	Buy	3.30	600	1,980	101,548	Dec 08 05:39 PM
Brandon George Hugh	President	Dec 03 '25	Buy	3.63	3,900	14,157	98,148	Dec 03 05:46 PM
Brandon George Hugh	President	Dec 01 '25	Buy	3.49	2,998	10,463	92,998	Dec 03 05:46 PM
Brandon George Hugh	President	Dec 02 '25	Buy	3.50	1,250	4,375	94,248	Dec 03 05:46 PM
James Jeremy William	Director	Aug 14 '25	Option Exercise	3.40	10,000	34,000	23,339	Nov 14 05:01 PM
Magennis Sean James	Director	Aug 14 '25	Option Exercise	3.40	10,000	34,000	30,000	Nov 14 04:57 PM
MARLETT CHRISTOPHER A	Co-Founder	Oct 03 '25	Buy	3.35	2,275	7,621	156,208	Oct 07 09:21 AM
MARLETT CHRISTOPHER A	Co-Founder	Oct 06 '25	Buy	3.41	1,725	5,882	157,933	Oct 07 09:21 AM
MARLETT CHRISTOPHER A	Co-Founder	Aug 29 '25	Buy	3.52	1,645	5,790	153,933	Aug 29 09:58 PM
MARLETT CHRISTOPHER A	Co-Founder	Aug 28 '25	Buy	3.56	1,575	5,607	152,288	Aug 29 09:58 PM
MARLETT CHRISTOPHER A	Co-Founder	Aug 26 '25	Buy	3.35	1,414	4,737	149,425	Aug 27 07:16 PM
MARLETT CHRISTOPHER A	Co-Founder	Aug 27 '25	Buy	3.40	1,288	4,379	150,713	Aug 27 07:16 PM
MARLETT CHRISTOPHER A	Co-Founder	Aug 25 '25	Buy	3.31	1,232	4,078	148,011	Aug 27 07:16 PM
MARLETT CHRISTOPHER A	Co-Founder	Aug 21 '25	Buy	3.45	1,200	4,140	145,579	Aug 22 04:12 PM
MARLETT CHRISTOPHER A	Co-Founder	Aug 22 '25	Buy	3.33	1,200	3,996	146,779	Aug 22 04:12 PM
MARLETT CHRISTOPHER A	Co-Founder	Jul 14 '25	Buy	4.42	100	442	144,379	Jul 15 09:02 PM
MARLETT CHRISTOPHER A	Co-Founder	Jun 26 '25	Buy	4.50	22	99	144,279	Jun 26 05:00 PM
MARLETT CHRISTOPHER A	Co-Founder	Jun 24 '25	Buy	4.46	20	89	144,255	Jun 26 05:00 PM
MARLETT CHRISTOPHER A	Co-Founder	Jun 25 '25	Buy	4.50	2	9	144,257	Jun 26 05:00 PM
MARLETT CHRISTOPHER A	Co-Founder	Jun 20 '25	Buy	4.13	888	3,667	143,558	Jun 24 02:11 PM
MARLETT CHRISTOPHER A	Co-Founder	Jun 23 '25	Buy	4.12	677	2,789	144,235	Jun 24 02:11 PM
MARLETT CHRISTOPHER A	Co-Founder	Jun 18 '25	Buy	4.04	635	2,565	142,670	Jun 20 11:08 AM
MARLETT CHRISTOPHER A	Co-Founder	Jun 12 '25	Buy	3.88	1,280	4,966	142,035	Jun 13 10:07 AM
MARLETT CHRISTOPHER A	Co-Founder	Jun 11 '25	Buy	3.83	1,270	4,864	140,755	Jun 13 10:07 AM
MARLETT CHRISTOPHER A	Co-Founder	Jun 10 '25	Buy	3.91	1,282	5,013	139,485	Jun 11 01:50 PM
MARLETT CHRISTOPHER A	Co-Founder	Jun 09 '25	Buy	3.83	13	50	138,203	Jun 11 01:50 PM
MARLETT CHRISTOPHER A	Co-Founder	Jun 02 '25	Buy	3.95	1,327	5,242	138,190	Jun 02 08:35 PM
MARLETT CHRISTOPHER A	Co-Founder	May 30 '25	Buy	3.90	1,305	5,090	136,863	Jun 02 08:35 PM
MARLETT CHRISTOPHER A	Co-Founder	May 28 '25	Buy	3.90	1,275	4,972	134,258	May 30 12:56 PM
MARLETT CHRISTOPHER A	Co-Founder	May 29 '25	Buy	3.69	1,300	4,797	135,558	May 30 12:56 PM
MARLETT CHRISTOPHER A	Co-Founder	Apr 11 '25	Buy	5.00	1,625	8,125	132,983	Apr 14 08:23 PM
DIGIANDOMENICO ANTHONY	Co-Founder	Apr 07 '25	Buy	4.90	1,425	6,983	95,699	Apr 09 06:21 PM
MARLETT CHRISTOPHER A	Co-Founder	Apr 07 '25	Buy	4.80	1,425	6,840	131,358	Apr 09 06:16 PM

PSEC

Prospect Capital Corp

IMRX

Immuneering Corp

RZLT

Rezolute Inc

AKTX

Akari Therapeutics Plc ADR

MDBH

MDB Capital Holdings LLC

Upgrade your FINVIZ experience